Overview of Antadys

Property	Description
Active Ingredient	Flurbiprofen
Form	Film-coated tablets
Pharmacological Class	Non-steroidal Anti-inflammatory Drug (NSAID)
Common Use	Symptomatic relief of pain, inflammation, and fever
Origin	Synthetic compound (Propionic acid derivative)

Antadys is a medicinal product defined by its sole active component, flurbiprofen, which is classified within the pharmaceutical category of Non-steroidal Anti-inflammatory Drugs (NSAIDs). It is a synthetic substance derived from propionic acid, designed for systemic use to manage discomfort arising from inflammatory processes. Antadys is typically recognized as a prescription-only medicine, differentiating it from many over-the-counter NSAID formulations.

Antadys: A Definition and Pharmacological Classification

Antadys is a pharmaceutical agent whose identity is rooted in the active substance Flurbiprofen. This compound acts as a prostaglandin synthesis inhibitor, a mechanism that is clinically recognized for effectively interrupting pain signals and inflammatory cascades. Flurbiprofen inhibits cyclooxygenase, working to block the chemicals that cause pain and inflammation. As a propionic acid derivative, the product is a single-ingredient preparation, concentrating its therapeutic effect entirely on the NSAID properties of Flurbiprofen.

Composition and Pharmaceutical Form

The medicinal product Antadys is presented as film-coated tablets intended for administration via the oral route. This solid dosage form ensures the systemic absorption of the active substance, allowing it to be distributed throughout the body to exert its anti-inflammatory and analgesic effects. The tablet's structure consists of the active ingredient and necessary solid pharmaceutical excipients that form the tablet matrix and the coating, providing a standardized mechanism of delivery. This specific formulation is approved for use in adults and adolescents, establishing its defined target patient group.

Core Purpose: Anti-inflammatory and Analgesic Action

The primary function of Antadys is to offer comprehensive symptomatic relief by utilizing its combined anti-inflammatory and analgesic effects. Its systemic use is generally intended to alleviate symptoms such as swelling and pain linked to inflammatory conditions. The drug also acts as an antipyretic agent to help manage elevated body temperature. Its benefit is derived from this versatile action profile, establishing it as a functional tool for reducing general discomfort linked to various inflammatory conditions.

What side effects are possible with Antadys?

Possible Side Effects and Safety Information

The safety profile for Antadys (flurbiprofen), a Non-steroidal Anti-inflammatory Drug (NSAID), is structured by official regulatory documents around potential adverse reactions in several key System-Organ Classes. These classifications provide the official framework for understanding the medicine’s risks.

Key Adverse Reaction Categories

Adverse reactions are formally classified by frequency and affected organ system:

Gastrointestinal Disorders: Effects are commonly documented, including dyspepsia, abdominal pain, diarrhea, and nausea. Serious events, such as gastrointestinal bleeding, ulceration, and perforation, are listed as potential risks that can occur at any time during use.
Nervous System Disorders: Headache and dizziness are frequently reported adverse reactions.
Cardiovascular and Vascular Disorders: The official label documents the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, a risk that may increase with the duration of use. The potential for new or worsening hypertension is also listed.
Renal Disorders: The potential for impaired renal function and nephrotoxicity is documented.

Serious and Population-Specific Safety Notes

Certain high-risk reactions and specific population considerations are noted in regulatory texts. Serious skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are documented as rare but possible events. Flurbiprofen is contraindicated in the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus. Furthermore, older adults are specifically noted in official documents as being at a greater risk for serious gastrointestinal and renal adverse reactions.

Overdose and Emergency Response

Official Overdose Manifestations

An overdose of Antadys (flurbiprofen) is officially documented to present with gastrointestinal (GI) and central nervous system (CNS) manifestations. Initial signs may include nausea, vomiting, stomach pain, heartburn, and unusual drowsiness, or a change in consciousness. Severe GI manifestations, such as bleeding, may be indicated by black or tarry stools or vomit that appears like coffee grounds.

Severe Outcomes and Emergency Action

The regulatory profile notes the potential for severe or life-threatening systemic outcomes, including seizures, prolonged loss of consciousness (coma), and serious complications like acute kidney injury and metabolic acidosis.

The official guidance mandates seeking immediate medical attention for a suspected overdose. Urgent medical help is required if the affected individual has collapsed, is having a seizure, has trouble breathing, or cannot be awakened. In all cases of suspected overdose, contacting emergency services is the required first step.

Management and Antidote Status

Due to the lack of a known specific antidote, treatment is officially designated as symptomatic and supportive to manage clinical symptoms and maintain vital functions. Hospital monitoring is often necessary to observe for and manage the development of severe systemic or GI complications.

Therapeutic Uses of Antadys

What Antadys Treats: Main Uses and Benefits

Antadys (flurbiprofen) is commonly used in areas where short-term symptom management is appropriate, particularly for symptoms related to inflammatory or irritative states. The medication's uses are applied across conditions where symptoms that interfere with daily functioning become noticeable.

It is commonly used across conditions characterized by periods of heightened symptoms to help manage discomfort associated with rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, and pain following dental surgery or soft tissue trauma. The medication is relevant for easing symptoms that interfere with daily comfort, offering short-term symptomatic assistance when symptoms become more disruptive during flare-ups.

Quick Fact: Relief for Inflammatory Discomfort

Antadys is applied in scenarios where additional management of discomfort is required, primarily assisting with pain, stiffness, swelling, and fever that accompany acute or chronic inflammatory episodes. This support helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

NIH MedlinePlus overview on flurbiprofen

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Antadys — Official Regulatory Information

The eligibility for Antadys (flurbiprofen) is determined by regulatory bodies based on a patient's medical history and physical state, defining strict exclusions for safety.

Eligibility Scope	Official Regulatory Status
Populations Allowed	Adults (18+); Adolescents ge 12 years (for some formulations).
Severe Organ Impairment	Contraindicated in patients with severe heart failure, severe hepatic failure, or severe renal failure.
Gastrointestinal History	Contraindicated with active or a history of recurrent peptic ulceration, GI hemorrhage, or perforation, including those related to previous NSAID therapy.
Hypersensitivity	Contraindicated with known hypersensitivity to flurbiprofen, aspirin, or any other Non-steroidal Anti-inflammatory Drug (NSAID).
Pregnancy	Contraindicated in the third trimester (from 30 weeks gestation). Use in the first and second trimesters is restricted.
Procedural Restriction	Contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Pediatric Use	Not recommended for children under 12 years; safety and efficacy are not established.
Geriatric Patients	Eligible, but use requires caution due to increased risk of serious adverse reactions (e.g., GI bleeding, renal issues).
Lactation	Not recommended (flurbiprofen is secreted in breast milk).

Connection to the overall eligibility profile: The regulatory profile strictly prohibits Antadys use when specific high-risk conditions are present, such as severe organ failure or a history of serious GI complications. Eligibility is also categorically denied during the third trimester of pregnancy and in specific surgical settings, while pediatric use is generally not supported by sufficient data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Antadys (Flurbiprofen) is formally documented by regulatory authorities, highlighting several clinically significant combinations and prohibitions, primarily driven by additive pharmacodynamic effects and pharmacokinetic alterations.

Official Regulatory Restrictions

Classification	Interacting Substance/Class	Documented Outcome
Contraindicated	Other NSAIDs (including COX-2 Inhibitors)	Increased risk of gastrointestinal bleeding and ulceration.
Contraindicated	Aspirin (> 75 mg/day for anti-inflammatory purposes)	Increased risk of gastrointestinal ulceration and bleeding.

Significant Interaction Categories

Co-administration with oral anticoagulants (e.g., Warfarin) is documented to potentiate the anticoagulant effect, leading to a heightened risk of bleeding. Similarly, combining Antadys with Antiplatelet Agents results in an additive risk of gastrointestinal bleeding.

Flurbiprofen may also interfere with therapeutic efficacy: combining it with Diuretics or Antihypertensives (ACE inhibitors, Angiotensin II Antagonists) may reduce their expected effects and pose a documented risk of impaired renal function.

Regarding systemic exposure, Flurbiprofen is metabolized via the CYP2C9 enzyme. Therefore, co-administration with CYP2C9 Inhibitors may increase flurbiprofen plasma concentrations. Furthermore, Antadys is documented to increase the exposure of co-administered Lithium and Methotrexate by reducing their renal clearance. A mandatory cautionary rule exists for the administration timing with low-dose Aspirin (75 mg/day) to avoid interference with its antiplatelet effect. An increased risk of gastrointestinal bleeding is also documented when Antadys is combined with alcohol.

Mechanism of Action

Antadys contains flurbiprofen, which functions as a nonsteroidal anti-inflammatory drug (NSAID). Its mechanism of action primarily involves modulating key pathways associated with the production of chemical mediators.

Enzyme-Mediated Signaling Inhibition

This domain involves the primary mechanism where the drug acts as an inhibitor of cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. By blocking these enzymes, the drug modifies the early molecular steps in the arachidonic acid cascade, which is the signaling sequence that produces eicosanoids.

Modulation of Key Mediator Production

The direct mechanistic consequence of COX enzyme inhibition is a significant reduction in the synthesis of prostaglandins and other eicosanoids. This reduced mediator activity facilitates a decrease in pathway activity, consequently restricting the formation of mediators responsible for heightened physiological responses.

Systemic Physiological Adjustment

The drug engages mechanisms that regulate overactive, dysregulated processes at a molecular level, resulting in alterations of local physiological parameters. This consequence influences the reduction of heightened local physiological reactions by attenuating systemic propagation of inflammatory mediators.

Dosage and Administration Information

How to Use Antadys

Antadys is administered via the oral route as a film-coated tablet. The medicine is used according to a structured dosing regimen that is generally divided across the day.

Official Dosing and Frequency

The standard adult dosing regimen typically falls in the range of 200 mg to 300 mg per day. The total daily dosage should not exceed 300 mg. This quantity is intended to be administered in divided doses, meaning the daily amount is typically split and taken two, three, or four times throughout the day. For acute and intermittent use, such as for primary dysmenorrhea, an initial dose of 100 mg may be taken, with subsequent doses of 50 mg or 100 mg allowed at four- to six-hour intervals as needed.

Administration Timing and Constraints

Administration of the tablet is recommended to occur with or after food or a full glass of water. It is a mandatory procedural constraint that the film-coated tablet must be swallowed whole to maintain the integrity of the dosage form and must not be cut, crushed, or chewed. Overall use is generally limited to the shortest duration necessary for symptom control, consistent with the usage principles for this class of non-steroidal anti-inflammatory drugs.

Age-Related Usage Principles

Dosing rules contain specific guidance for certain patient populations. The product is not recommended for use in children under 12 years of age. For older adults, treatment is structured to begin with the lowest effective dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Antadys (Flurbiprofen)

Evidence for Managing Primary Dysmenorrhea

Studies of flurbiprofen for painful menstruation, or primary dysmenorrhea, have primarily focused on short-term, randomized controlled trials (RCTs) and systematic reviews. These studies were applied in research examining patient-reported experiences related to acute pain. Researchers monitored outcomes related to physical discomfort, using scales to measure pain intensity, and tracked whether subjects needed to take supplementary pain medication.

Studies conducted during periods of increased symptom activity reported various findings describing patterns observed in the studies related to pain scores. This evidence contributes to the broader evidence landscape of how flurbiprofen was evaluated for conditions characterized by episodic or acute manifestations. However, the existing research provides limited insight into long-term outcomes for this condition, as follow-up durations were limited.

Evidence for Symptom Management in Rheumatoid Arthritis and Osteoarthritis

For managing symptoms in Rheumatoid Arthritis and Osteoarthritis, the research structure includes medium-term RCTs and systematic reviews. Studies explored outcomes reflecting daily functioning or activity level, alongside measures of pain, joint swelling, and stiffness. Findings from these studies describe patterns observed in how symptoms evolved in the observed populations during the defined study periods.

The research primarily focused on symptom changes and did not characterize long-term functional outcomes or potential effects on disease progression. Despite this, the evidence for these conditions focuses largely on symptomatic relief over short to intermediate periods (often a few weeks to several months).

Evidence for Acute Postoperative and Dental Pain Relief

The evidence base for acute pain, such as pain following dental procedures, includes numerous very short-term, standardized RCTs. Researchers studied the precise timing of the onset of pain relief and how long that relief was observed, alongside the necessity for rescue medication. The data show highly consistent patterns related to time-to-onset and duration of measured relief in these controlled settings.

Key Limitations and Areas of Research Uncertainty

The overall evidence landscape includes studies documenting short-term symptom patterns, alongside several key limitations. Follow-up durations were often limited, and the research provides limited insight into long-term functional outcomes across many of its applications. The available evidence helps characterize what has been studied—and what remains uncertain—about flurbiprofen's clinical evaluation.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Antadys (FAQ)

Q: Is Antadys used for treatment of back pain or sciatica?

A: Regulatory documents indicate that the active ingredient in Antadys is used for symptomatic relief in various musculoskeletal conditions. This range of uses typically includes general joint and muscle pain, such as that associated with low back pain. Official information is used to define the appropriate conditions.

Q: Why do I need a prescription for Antadys when other NSAIDs are over-the-counter?

A: Official regulatory labels classify Antadys as a prescription-only medicine. This means that unlike some other NSAIDs (Non-steroidal Anti-inflammatory Drugs), official guidance requires a doctor's prescription for the medicine to be dispensed. The available regulatory documentation does not typically include the specific rationale behind the drug’s prescription classification.

Q: Does the active ingredient in Antadys have other brand names?

A: Yes, the active ingredient in Antadys is Flurbiprofen. This pharmaceutical compound is marketed and sold under various other brand names around the world, depending on the country and formulation.

Q: Is Antadys an opioid or a narcotic painkiller?

A: Official sources classify Antadys as a Non-steroidal Anti-inflammatory Drug (NSAID). It is a synthetic substance derived from propionic acid and is not classified as an opioid or a narcotic painkiller.

Q: Is Antadys a steroidal medication?

A: No. Antadys is classified by regulatory authorities as a Non-steroidal Anti-inflammatory Drug, or NSAID. The 'Non-steroidal' part of this classification indicates that it does not contain or function as a steroid.

Q: Does Antadys cause drowsiness or make it difficult to drive?

A: Official product information notes that certain nervous system disorders, including dizziness and drowsiness, are listed as reported side effects. Regulatory documents note that these effects may impair a person’s ability to perform tasks that require alertness, such as driving or operating machinery.

Q: Can taking Antadys cause fluid retention or swelling?

A: Official adverse reaction reports document the occurrence of edema, which is the medical term for fluid retention or swelling of the body. Edema is listed as a commonly reported event in clinical studies involving the drug.

Q: Are there any known long-term side effects from using Antadys?

A: Official regulatory warnings advise that using NSAIDs for extended periods is associated with an increased risk of serious adverse events. These serious risks can involve cardiovascular issues, such as heart attack or stroke, and serious gastrointestinal problems, such as bleeding or ulcers.

Q: Is hair loss a reported side effect of Antadys?

A: Official post-marketing surveillance reports have included instances of alopecia (hair loss). The frequency of this reported side effect is often not explicitly categorized in the primary labeling.

Q: Can Antadys cause skin rashes or allergic reactions?

A: Yes. Official documentation confirms that skin rash is a common dermatologic side effect. Furthermore, the drug is formally contraindicated in people with a history of allergic-type reactions to aspirin or other NSAIDs, meaning its use is not permitted under those conditions.

Q: How often do people experience nausea or vomiting with Antadys?

A: Regulatory adverse event summaries indicate that nausea is one of the most frequently reported side effects. This indicates that nausea is observed in a high percentage of individuals studied, according to clinical trial summaries.

Q: Does Antadys interact with Selective Serotonin Reuptake Inhibitors (SSRIs)?

A: Yes, regulatory documents list an interaction with certain types of antidepressant medicines, including SSRIs. Co-administration with SSRIs may increase the overall risk of bleeding.

Q: Is it safe to consume alcohol while taking Antadys?

A: Official documentation states that co-administration with alcohol has been associated with an increased risk of serious gastrointestinal bleeding. Regulatory information is used to define these interactions.

Q: Are there known food interactions with Antadys?

A: Regulatory pharmacokinetic data indicate that the rate at which the body absorbs the medicine is slowed down when the tablets are taken with food. However, this action does not generally alter the total amount of medicine that is absorbed.

Q: Does the onset of action differ when taking Antadys with food?

A: Since regulatory information states that food can slow down the rate of absorption, this reduction in the rate of absorption may subsequently affect the time until the initial effects of relief are observed.

Q: Are there known risks associated with Antadys for people with a history of asthma?

A: Yes. The drug is formally contraindicated by regulatory bodies for use in patients with a known history of asthma, nasal polyps, or other allergic-type reactions that occurred after taking aspirin or other NSAIDs.

Q: Is Antadys gluten-free or suitable for people with lactose intolerance?

A: Official product excipient lists, which detail the inactive ingredients, may include substances like lactose in some formulations. For individuals with specific sensitivities, checking the excipient list for the specific product formulation is noted as necessary.

Q: Why is the active ingredient in Antadys sometimes used in eye drops?

A: The active ingredient, flurbiprofen, is not only used in oral tablets but is also formulated as an ophthalmic solution (eye drops). Regulatory indications for the eye drop formulation include its use to prevent miosis (excessive pupil constriction) during certain eye surgeries.

Q: What research has been conducted on the safety profile of Antadys in long-term use?

A: Official warnings about long-term use are informed by clinical trial data and post-marketing surveillance reports. This safety data contributes to regulatory guidance regarding the documented risks of serious events, particularly those affecting the cardiovascular, renal, and gastrointestinal systems.

Q: Can Antadys be used to treat headache pain?

A: The oral tablet form of Antadys is typically indicated for pain relief related to inflammatory and musculoskeletal conditions. The official label for the oral tablet does not list headache as a primary use, and headache is frequently noted as an adverse reaction.

Q: Can men take Antadys, or is it only for women's pain?

A: Official regulatory documents approve the use of Antadys for adults and adolescents aged 12 and older. The medicine’s anti-inflammatory and analgesic effects are relevant to all patients, regardless of gender.

Q: What is the official guidance on using Antadys during pregnancy or breastfeeding?

A: Regulatory guidance prohibits the use of Antadys during the third trimester of pregnancy due to risks to the fetus. Use during the first and second trimesters is restricted and generally should be avoided. The medicine is also generally not recommended during lactation, as the active substance is known to be secreted into breast milk.

How should Antadys be stored and disposed of?

How to Store and Dispose of Antadys (Flurbiprofen)

The medicine's storage and disposal requirements are established by regulatory labeling to ensure product integrity.

Storage Requirements

Requirement Category	Official Storage Statement
Temperature	Store below 25 C or below 30 C and keep from freezing.
Environmental Control	The tablets must be protected from light and moisture.
Packaging	Keep the medicine in its original container and ensure it is tightly closed.
Child Safety	Keep Antadys out of the sight and reach of children at all times.

Disposal Instructions

Disposal of unused or expired Antadys must be carried out in accordance with local requirements. The product should generally not be discarded via wastewater or household trash unless specifically instructed by the labeling. Utilizing an official drug take-back program is the recommended method for disposal.

Antadys